E
Bicycle Therapeutics plc BCYC
$9.69 $0.060.62%
Recommendation
Sell
Prev Close
$9.63
Volume
629,111
Avg Vol (90D)
474,717
Market Cap
$666.42M
Dividend & Yield
--
52-Week Range
$9.58 - $28.67
P/E (TTM)
--
EPS (TTM)
-$2.88
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Bicycle Therapeutics (BCYC, $9.63) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 13, 2025
3/14/2025 - Tickeron - Stocks
Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 6% - Here's Why
3/13/2025 - MarketBeat
Bicycle Therapeutics (BCYC, $10.4) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 12, 2025
3/13/2025 - Tickeron - Stocks
Bicycle Therapeutics (NASDAQ:BCYC) Receives Buy Rating from Needham & Company LLC
3/12/2025 - MarketBeat
Bicycle Therapeutics (BCYC, $10.2) RSI Indicator left the oversold zone on March 11, 2025
3/12/2025 - Tickeron - Stocks
Bicycle Therapeutics (NASDAQ:BCYC) Hits New 12-Month Low - What's Next?
3/10/2025 - Ticker Report
Bicycle Therapeutics (NASDAQ:BCYC) Sets New 12-Month Low - What's Next?
3/10/2025 - MarketBeat
Bicycle Therapeutics (BCYC, $10.23) RSI Indicator left the oversold zone on March 07, 2025
3/8/2025 - Tickeron - Stocks
Bicycle Therapeutics (BCYC, $10.65) RSI Indicator left the oversold zone on March 06, 2025
3/7/2025 - Tickeron - Technical Analysis
Bicycle Therapeutics (BCYC, $10.65) RSI Indicator left the oversold zone on March 06, 2025
3/7/2025 - Tickeron - Stocks
Candriam S.C.A. Raises Position in Bicycle Therapeutics plc (NASDAQ:BCYC)
3/7/2025 - MarketBeat
B. Riley Predicts Reduced Earnings for Bicycle Therapeutics
3/6/2025 - MarketBeat
We Did The Math BMED Can Go To $32
3/5/2025 - ETF Channel
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/5/2025 - GuruFocus
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/5/2025 - Business Wire
Principal Financial Group Inc. Lowers Position in Bicycle Therapeutics plc (NASDAQ:BCYC)
3/4/2025 - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Reaches New 52-Week Low - Should You Sell?
3/3/2025 - MarketBeat
Q1 EPS Estimate for Bicycle Therapeutics Reduced by Analyst
3/1/2025 - MarketBeat
Bicycle Therapeutics plc (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages
3/1/2025 - MarketBeat
Bicycle Therapeutics (BCYC, $11.03) RSI Indicator left the oversold zone on February 27, 2025
2/28/2025 - Tickeron - Stocks
Bicycle Therapeutics (BCYC, $11.03) Moving Average Convergence Divergence (MACD) Histogram turned negative on February 27, 2025
2/28/2025 - Tickeron - Stocks
Bicycle Therapeutics (NASDAQ:BCYC) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS
2/27/2025 - Ticker Report
Bicycle Therapeutics (BCYC, $11.32) RSI Indicator left the oversold zone on February 26, 2025
2/27/2025 - Tickeron - Stocks
Bicycle Therapeutics (NASDAQ:BCYC) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS
2/26/2025 - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Given Buy Rating at Needham & Company LLC
2/26/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$35.28M
EBITDA (TTM)
-$202.70M
EBIT (TTM)
-$209.87M
Net Income (TTM)
-$169.03M
Balance Sheet
Total Assets (Q)
$956.87M
Total Debt (Q)
$13.48M
Total Liabilities (Q)
$163.81M
Book Value Per Share (Q)
$11.48
Cash Flow
Cash from Operations (TTM)
-$164.72M
Cash from Investing (TTM)
-$1.24M
Cash from Financing (TTM)
$519.75M
Net Change in Cash (TTM)
$353.10M
Filings
Filing Date
Tuesday, February 25, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Beginning of May (est)
Price History
Loading...
Beta
0.96
7-Day Total Return
-6.65%
30-Day Total Return
-24.12%
60-Day Total Return
-29.83%
90-Day Total Return
-58.67%
Year to Date Total Return
-32.52%
1-Year Total Return
-57.76%
2-Year Total Return
-55.26%
3-Year Total Return
-77.24%
5-Year Total Return
-27.79%
52-week Low
Mar 10, 2025 - $9.58
52-week High
Oct 16, 2024 - $28.67
Valuation
Market Cap
$666.42M - Small Cap
Enterprise Value
-$203.61M
Price/Sales (TTM)
18.85
Price/Book (Q)
0.84
Dividends and Shares
Shares Outstanding
69.05M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.bicycletherapeutics.com
Phone Number
44 1223 261 503
Address
Portway Building
Blocks A & B - Granta Park
Great Abington Cambridge, CB21 6GS
Country
United Kingdom
Year Founded
2009
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United... more
NASDAQ 03/14/2025 4:00PM Eastern Quotes delayed
Weiss Ratings